Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

BACKGROUND: The cost of new anticancer drugs is rising. We aimed to assess the clinical benefit and price of anti‐cancer drugs approved by the US Food and Drug Administration (FDA) for advanced gastrointestinal cancers. METHODS: Drugs approved between 2006 and 2017 for advanced GI malignancies were...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Di Maria, Chan, Kelvin K. W., Jang, Raymond W., Booth, Christopher, Liu, Geoffrey, Amir, Eitan, Mason, Robert, Everest, Louis, Elimova, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488126/
https://www.ncbi.nlm.nih.gov/pubmed/30848108
http://dx.doi.org/10.1002/cam4.2058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488126/
https://www.ncbi.nlm.nih.gov/pubmed/30848108
http://dx.doi.org/10.1002/cam4.2058

Ejemplares similares